Cargando…

Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes

Detalles Bibliográficos
Autores principales:	Ong, Sean Wei Xiang, Young, Barnaby Edward, Lye, David Chien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041357/ https://www.ncbi.nlm.nih.gov/pubmed/33857407 http://dx.doi.org/10.1016/S1473-3099(21)00201-2

Ejemplares similares

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

SARS-CoV-2 antibody seroprevalence in patients receiving dialysis in the USA
por: Flower, Barnaby, et al.
Publicado: (2020)

Decoding the next SARS-CoV-2 variant
por: Nel, Jeremy, et al.
Publicado: (2022)

SARS-CoV-2 variants and ending the COVID-19 pandemic
por: Fontanet, Arnaud, et al.
Publicado: (2021)

Transmission of Omicron (B.1.1.529) - SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19
por: Wong, Shuk-Ching, et al.
Publicado: (2021)

SARS-CoV-2 variants and considerations of inferring causality on disease severity
por: Cevik, Muge, et al.
Publicado: (2021)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
por: Hoehl, Sebastian, et al.
Publicado: (2023)

The devil's in the details
por: Petsko, Gregory A
Publicado: (2010)

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines
por: Thiruvengadam, Ramachandran, et al.
Publicado: (2022)

Travel measures in the SARS-CoV-2 variant era need clear objectives
por: Kucharski, Adam J, et al.
Publicado: (2022)

Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity
por: Markov, Peter V., et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?
por: Wilder-Smith, Annelies
Publicado: (2022)

Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants
por: Lechien, Jérôme R, et al.
Publicado: (2022)

Understanding how fast SARS-CoV-2 variants transmit from household studies
por: Yang, Yang, et al.
Publicado: (2022)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

SARS-CoV-2 variants offer a second chance to fix vaccine inequities
por: Hotez, Peter J.
Publicado: (2022)

Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy
por: Yadav, Pragya D, et al.
Publicado: (2022)

SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence
por: Vargas-Herrera, Natalia, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced antibody levels: what lies beneath
por: Lassaunière, Ria, et al.
Publicado: (2022)

Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages
por: Jewell, Britta L
Publicado: (2021)

New year, new SARS-CoV-2 variant: Resolutions on genomic surveillance protocols to face Omicron
por: Oróstica, Karen Y., et al.
Publicado: (2022)

Targeted mass testing and phylogenetic analysis is effective for preventing community transmission of SARS‐CoV‐2 beta variant
por: Tokuda, Yasuharu, et al.
Publicado: (2022)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

So far, no novel SARS-CoV-2 variants from Beijing—and hopefully better scientific cooperation going forward
por: Preiser, Wolfgang, et al.
Publicado: (2023)

Real-world effectiveness of nirmatrelvir–ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants
por: Wong, Carlos K H, et al.
Publicado: (2023)

Asymptomatic SARS-CoV-2 infection
por: Ooi, Eng Eong, et al.
Publicado: (2020)

The complexities of SARS-CoV-2 serology
por: Houlihan, Catherine F, et al.
Publicado: (2020)

Neonatal SARS-CoV-2 infection
por: de Carvalho, Werther Brunow, et al.
Publicado: (2020)

Towards SARS-CoV-2 serotypes?
por: Simon-Loriere, Etienne, et al.
Publicado: (2022)

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID
por: Ward, Helen, et al.
Publicado: (2021)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France
por: Lefèvre, Benjamin, et al.
Publicado: (2021)

What do we know about pathological mechanism and pattern of lung injury related to SARS-CoV-2 Omicron variant?
por: Scendoni, Roberto, et al.
Publicado: (2023)

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2
por: Anderson, Danielle E., et al.
Publicado: (2020)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

Understanding the drivers of transmission of SARS-CoV-2
por: Cornelissen, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l5a2tni525ao2335orbf7sbvit